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Abstract
Background: In streptococci, three macrolide resistance determinants (erm(B), erm(TR) and
mef(A)) have been found. In addition, certain mutations at the ribosomal 23S RNA can cause
resistance to macrolides. Mutation at the position 2058 of the 23S rRNA of the Streptococcus
pyogenes as a cause of macrolide resistance has not been described before.
Methods: Antibiotic resistance determinations for the clinical S. pyogenes strain ni4277 were done
using the agar dilution technique. Macrolide resistance mechanisms were studied by PCR and
sequencing. All six rRNA operons were amplified using operon-specific PCR. The PCR products
were partially sequenced in order to resolve the sequences of different 23S rRNA genes.
Results: One clinical isolate of S. pyogenes carrying an adenine to guanine mutation at the position
2058 of the 23S rRNA in five of the six possible rRNA genes but having no other known macrolide
resistance determinants is described. The strain was highly resistant to macrolides and azalides,
having erythromycin and azithromycin MICs > 256 microgram/ml. It was resistant to lincosamides
(clindamycin MIC 16 microgram/ml) and also MIC values for ketolides were clearly elevated. The
MIC for telithromycin was 16 microgram/ml.
Conclusion: In this clinical S. pyogenes strain, a mutation at the position 2058 was detected. No
other macrolide resistance-causing determinants were detected. This mutation is known to cause
macrolide resistance in other bacteria. We can conclude that this mutation was the most probable
cause of macrolide, lincosamide and ketolide resistance in this strain.
Background
Streptococcus pyogenes (group A streptococcus) is an impor-
tant pathogen causing pharyngitis, scarlet fever, impetigo,
erysipelas, cellulitis and necrotizing fasciitis. S. pyogenes
throat infection can lead to suppurative complications
like peritonsillar cellulitis and abscesses [1]. Nonsuppura-
tive complications of streptococcal pharyngitis, acute
rheumatic fever and glomerulonephritis are rare [2]. S.
pyogenes can also colonize the throats of asymptomatic
persons [1]. The treatment of S. pyogenes infections relies
on penicillin [3], which has retained its antimicrobial
activity and is the drug of choice [4]. Macrolide antibiotics
are used to treat patients with allergies to penicillin. In
contrast to penicillin, resistance to macrolides among S.
pyogenes strains has become an increasing problem [5,6].
There are two main acquired macrolide resistance mecha-
nisms in S. pyogenes, posttranscriptional target site
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modification and macrolide efflux [6]. Target site modifi-
cation is mediated by erythromycin resistance methylase
(erm) genes. In S. pyogenes, two different Erm methylases
have been found. Erm(B) methylase encoded by the
erm(B) gene belongs to the Erm(B) class of rRNA methyl-
ases, and causes resistance to macrolides, lincosamides
and streptogramin B antibiotics, i.e. the MLSB type of
resistance. Erm(TR) methylase belongs to the Erm(A)
class of rRNA methylases, and also causes the MLSB type of
resistance [7]. However, the type of resistance depends
also on the expression type of the Erm methylase. erm(B)
and erm(TR) genes of the inducible type usually cause
resistance only to erythromycin and other 14- and 15-
membered-ring macrolides but not to lincosamides and
streptogramin B antibiotics [5]. After induction of the
expression of the gene by sub-inhibitory concentration of
erythromycin, these genes cause resistance also to lincosa-
mides and streptogramin B antibiotics [8]. The other main
acquired resistance mechanism, macrolide efflux, is medi-
ated by mef(A) resistance genes [7]. mef(A) genes cause the
M type of resistance, i.e. resistance against 14- and 15-
membered-ring macrolides [9]. In addition to mef(A)
mediated macrolide efflux, Giovanetti et al. [10] have
demonstrated the presence of a putative novel efflux sys-
tem, associated with erm(TR) gene in S. pyogenes. The gene
or genes behind this erythromycin efflux system are not
yet known.
Mutations at the ribosomal proteins (L4 and L22) and
23S rRNA are known to cause macrolide reistance in strep-
tococci [11,12]. In S. pyogenes, mutations at the ribosomal
protein L4 and a mutation at the position 2611 of the 23S
rRNA as a cause of macrolide resistance have been
described before [13,14]. In this work, we describe one
clinical S. pyogenes strain resistant to macrolides, lincosa-
mides, streptogramin B antibiotics (quinupristin) and tel-
ithromycin with none of the known acquired
erythromycin resistance methylases or macrolide efflux
pumps, but having a mutation at the position 2058 of the
23S rRNA. This mutation has not been described before to
cause macrolide resistance in S. pyogenes.
Material and methods
Bacterial strains
Macrolide-resistant  Streptococcus pyogenes strain ni4277
was isolated from a throat specimen in the clinical micro-
biology laboratory of the Helsinki University Central Hos-
pital. Identification of the strain was based on the colony
morphology and hemolysis on Blood Agar Base (Oxoid
Ltd., Basingstoke, Hampshire, England) plate supple-
mented with 7,5% sheep blood as well as resistance to
bacitracin (A/S Rosco, Taastrup, Denmark) and positive
reaction in group A antigen test (Streptex ZL51, Murex
Biotech Ltd., Dartford, England). The identification was
further confirmed by sequencing the 23S rRNA genes (see
results and discussion). S. pyogenes strain ATCC 700294,
the whole genome of which has been sequenced, was pur-
chased from the American Type Culture Collection and
was used as a macrolide-susceptible control strain. Other
bacterial strains with different macrolide resistance deter-
minants were Escherichia coli with plasmid pJIR (erm(B)),
Staphylococcus simulans 13044 with plasmid pPV142
(erm(C)), E. coli with plasmid pEM9592 (erm(A)), S. pyo-
genes A200 (erm(TR)), S. pyogens A569 (mef(A)) and Sta-
phylococcus epidermidis A33 (msr(A)). These strains were
used as positive controls in different PCRs [12].
MIC testing and phenotyping
MIC testing was done using the agar-dilution technique
[15]. The bacteria were cultured 20 hours in air at 35°C on
Mueller-Hinton II (Becton Dickinson Microbiology Sys-
tems, Cockeysville, MD, USA) agar plates supplemented
with 5% sheep blood. The antibiotics used were: clin-
damycin, josamycin, telithromycin, HMR3004 (Aventis
Pharma, Romainville Cedex, France), azithromycin
(Pfizer, Groton, CT, USA), quinupristin, spiramycin
(Rhône-Poulenc Rorer, Vitrysur-Seine, France), erythro-
mycin, lincomycin (Sigma-Aldrich Chemie, Gmbh, Stein-
heim, Germany). The double-disk method with
erythromycin (diffusible content 78 µg) and clindamycin
(diffusible content 25 µg) (Rosco Neo-Sensitabs, A/S
Rosco, Taastrup, Denmark) discs was used for classifica-
tion of macrolide resistance phenotypes. The disks were
placed 15–20 mm apart on Mueller-Hinton II agar plates
supplemented with 5% sheep blood. Bacteria were cul-
tured 20 hours at 35°C. After incubation, blunting of the
clindamycin zone of inhibition proximal to the erythro-
mycin disk was interpreted to indicate inducible MLSB
resistance. NCCLS breakpoints, if available, were used for
interpretation of the MIC results [16].
PCR detection of macrolide resistance determinants
The presence of macrolide resistance genes erm(B),
erm(C), erm(A), erm(TR), mef(A) and mrs(A) were deter-
mined by PCR as described earlier [12]. Amplification of
the six ribosomal RNA (rRNA) operons were done using
long-range PCRs. Six different PCRs were needed for
amplification of six different rRNA operons. The PCRs
were identical except for the operon-specific primer. For
each rRNA operon, there was one common primer,
located at the beginning of the 23S rRNA molecule, and
one operon-specific primer (table 1). To obtain high qual-
ity DNA for long-range PCR, bacterial cells were cultivated
overnight in 10 ml of BHI broth (BD Bioscience, Sparks,
MD, USA). Cells were collected by centrifugation and the
DNA was isolated as described before [8]. Long-range
PCRs were done using DyNazyme Ext DNA polymerase
and the buffer supplied with the polymerase (Finnzymes
OY, Espoo Finland). The reaction volume was 50 µl, con-
taining 200 ng of the template DNA, 0,5 µM of operon-Annals of Clinical Microbiology and Antimicrobials 2004, 3 http://www.ann-clinmicrob.com/content/3/1/5
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specific primer and 0,5 µM of common 23S rRNA primer
(table 1), 3 U of the polymerase and 200 µM of each
nucleotide. The MgCl2 concentration was 1,5 mM. PCR
conditions were as follows: 1 minute at 94°C (one cycle),
20 seconds at 94°C, 30 seconds at 58°C and 3 minutes at
72°C (35 cycles). Amplification was performed using a
PTC-200 (MJ Research, Massachusetts, USA). The rRNA
operon specific PCR primers were designed using Gene-
Composer v. 1.1 [17] and the genome sequence of the S.
pyogenes  (accession number AE004092) strain SF370
(same as ATCC 700294) [18].
Amplification of the genes coding for ribosomal proteins
L4 and L22 was done using DyNazyme DNA polymerase
and buffer supplied with the polymerase (Finnzymes OY,
Espoo Finland). The reaction volume was 100 µl, contain-
ing 200 ng of the template DNA, 0,2 µM of each primer
(table 1), 1 U of the polymerase and 200 µM of the each
nucleotide. MgCl2 concentration was 1,5 mM. PCR condi-
tions were as follows: 1 minute at 94°C, 1 minute at 55°C
and 1 minute at 72°C (35 cycles). Amplification was per-
formed using the PTC-200.
Sequencing of the 23S rRNA, L4 and L22 genes
Sequencing was performed using an ABI Prism BigDye
Terminator Kit (Applied Biosystems, Foster City, CA,
USA) according to the manufacturer's instruction.
Sequencing primers are presented in table 1. Sequences
were handled using Vector NTi software (InforMax Inc,
Bethesda, MD, USA) and the GeneComposer software.
Comparisons to bacterial genome sequences were done
with the sequence similarity and homology searching
tools (Proteomes & Genomes Fasta) using a www-inter-
face to the European Bioinformatics Institute genome
database [19].
Accession numbers for the 23S rRNA gene sequences of
the strains ni4277 and ATCC 700294, submitted to the
EMBL nucleotide sequence database are AJ544681 and
AJ544682, respectively. Accession numbers for the genes
coding for L4 and L22 proteins of the strains ni4277 are
AJ544683 and AJ544684, respectively.
Results
The S. pyogenes strain ni4277 was highly resistant to all
macrolides and azalides. MICs were: erythromycin >256
µg/ml, spiramycin 64 µg/ml, josamycin 64 µg/ml, azi-
Table 1: PCR and sequencing primers
Primer Target gene Position Use Sequence (5'-3') Reference
23Scom a 23S rRNA 6-26b PCR/Seq AGTTAATAAGGGCGCACGGTG This work
23Sg1 c 23S rRNA gene1 1577119-157741d PCR/Seq AAGACGTATTGAAGCTTACTCTA This work
23Sg2 c 23S rRNA gene2 22879-22857 d PCR/Seq AGCTACTTCCCGAACTGATGCAC This work
23Sg3 c 23S rRNA gene3 29128-29106 d PCR/Seq GATAACCGTCTTCTTTCCCCTTT This work
23Sg4 c 23S rRNA gene4 85192-85170 d PCR/Seq CATATTTCTAACACGGGCAGTAG This work
23Sg5 c 23S rRNA gene5 270607-270582 d PCR/Seq CACTGCCAAGCTATCTAAACGTA This work
23Sg6 c 23S rRNA gene6 1330037-1330059d PCR/Seq CAATTGAATAGCCTGCACGTTCG This work
MS2 e 23S rRNA 550-573b Sequencing CGTGTGCCTACAACAAGTTCGAGC This work
MS3 e 23S rRNA 573-550b Sequencing GCTCGAACTTGTTGTAGGCACACG This work
MS4 e 23S rRNA 1016-997b Sequencing TTTCGACTACGGATCTTAGC [11]
MS5 e 23S rRNA 867-885b Sequencing CTGTTTGGGTGAGGGGTCC [11]
MS6 e 23S rRNA 1424-1446b Sequencing GGACGCAGTAGGCTAACTAAACC This work
MS7 e 23S rRNA 1446-1424b Sequencing GCTTTAGTTAGCCTACTGCGTCC This work
MS8 e 23S rRNA 2021-2040b Sequencing ACCTGCATCTTCACAGGTAC [11]
MS9 e 23S rRNA 1902-1921b Sequencing CGGCGGCCGTAACTATAACG [11]
MS10 e 23S rRNA 2415-2437b Sequencing GCCATCGCTCAACGGATAAAAGC This work
MS11 e 23S rRNA 2437-2415b Sequencing GCTTTTATCCGTTGAGCGATGGC This work
MS12 e 23S rRNA 2904-2880b Sequencing TTGGATAAGTCCTCGAGCTATTAG [11]
L4fu L4 64481-64498c PCR/Seq GCAAACACAGCTCCTAAG This work
L4rd L4 65751-65734c PCR/Seq CTGTGTAACGACCAACGC This work
L4f156 L4 65074-65091c Sequencing AACCGTTCAGCAGTATCA This work
L4r444 L4 65307-65290c Sequencing TGAAAGGCCTTCTACAGC This work
L22-1 L22 67079-67098c PCR/Seq GCAGACGACAAGAAAACACG [11]
L22-2 L22 67500-67481c PCR/Seq ATTGGATGTACTTTTTGACC [11]
a A PCR primer common to all 23S rRNA genes b Position in the 23S rRNA molecule (E. coli accession number J01695, numbering). c rRNA operon 
spesific PCR primers, artificial numbering of the 23S rRNA genes of the S. pyogenes d Position in the S. pyogenes genome (accession number 
AE004092). e23S rRNA gene sequencing primersAnnals of Clinical Microbiology and Antimicrobials 2004, 3 http://www.ann-clinmicrob.com/content/3/1/5
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thromycin >256 µg/ml. This strain had elevated MICs for
ketolides (telithromycin MIC 16 µg/ml and HMR3004
MIC 4 µg/ml). At the moment, NCCLS does not have
breakpoints for telithromycin [16]. However, the high
MIC value suggests that this strain is resistant to telithro-
mycin. It was also resistant to lincosamides (clindamycin
MIC 16 µg/ml and lincomycin MIC > 64 µg/ml), and it
showed elevated MIC for streptogramin B antibiotic,
quinupristin MIC 4 µg/ml. When tested with the erythro-
mycin-clindamycin double-disk method, the resistance
phenotype in the strain ni4277 was non-inducible. The S.
pyogenes strain ATCC 700294 was used as a macrolide sus-
ceptible control strain. The susceptibility of this strain was
confirmed by MIC testing. MICs for various antibiotics
were: erythromycin 0,063 µg/ml, spiramycin 0,25 µg/ml,
josamycin 0,25 µg/ml, azithromycin 0,125 µg/ml, tel-
ithromycin 0,008 µg/ml, HMR3004 0,008 µg/ml, clin-
damycin 0,031 µg/ml, lincomycin 0,063 µg/ml and
quinupristin 0,25 µg/ml. Thus, the MIC values for mac-
rolides, lincosamides, ketolides and quinupristin were
much higher in the strain ni4277 than in the strain ATCC
700294. The strain ATCC 700294 has no macrolide resist-
ance determinants in its genome. Neither has it known
macrolide-causing mutations in the ribosomal proteins
(L4 or L22) or 23S rRNA [18].
In  S. pyogenes, three macrolide resistance determinants
have been described thus far: erm(B), erm(TR) and mef(A)
[6]. Using PCR conditions that gave positive results from
positive control strains, none of these known macrolide
resistance genes was found in the S. pyogenes strain
ni4277. In addition, PCRs for macrolide resistance genes
(erm(A), erm(C) and msr(A)), known to cause resistance
in other gram-positive bacteria gave negative results,
although PCRs from corresponding control strains were
positive.
S. pyogenes has six operons coding for ribosomal RNA
molecules [18]. Based on the genome sequence data,
primers specific for each rRNA operon were designed
(table 1). In order to confirm the specificity of each
operon-specific PCR, a short fragment of each PCR prod-
uct was sequenced using the corresponding operon-spe-
cific primer. The sequences were compared to the genome
sequence of S. pyogenes. These confirmations were done
for macrolide-resistant strain ni4277 and for the strain
ATCC 700294, the genome sequence of which is available
[18]. These sequences confirmed that each operon specific
PCR amplified a different ribosomal operon.
The operon-spesific PCRs were used to amplify all the six
rRNA operons of the macrolide-resistant strain ni4277.
Both DNA strands of the 23S rRNA genes of each six oper-
ons were sequenced using 23S rRNA specific sequencing
primers (table 1). At least 2854 nucleotides between posi-
tions 52 and 2904 of the 23S rRNA gene (E. coli, accession
number J01695, numbering) from each of the six 23S
rRNA coding genes were sequenced. When the six 23S
rRNA gene sequences of the different rRNA operons of the
strain ni4277 were compared to each other, five of the
genes were found to be identical. The remaining 23S rRNA
gene differed from the other five genes in one position. All
the five 23S rRNA genes had guanine residue at the posi-
tion 2058 (E. coli numbering), whereas adenine residue
was found at the corresponding position in the one
operon. So, in five of the six 23S rRNA genes of the mac-
rolide-resistant strain ni4277, there was adenine to gua-
nine mutation at the position 2058. This mutation is
known to cause macrolide resistance, for example, in S.
pneumoniae [11]. The sequencing of all the six 23S rRNA
genes of the strain ni4277 was done twice. Both times
identical sequences were obtained from different operons
(five operons with guanine at the position 2058 and one
operon with adenine at the corresponding position).
Operon-specific PCRs were also used to amplify 23S rRNA
genes of the macrolide-susceptible control strain ATCC
700294. Both DNA strands of all the six 23S rRNA genes
of this strain were sequenced. When the sequences (at
least 2854 nucleotides between positions 52 and 2904) of
these six 23S rRNA genes were compared to each other,
they were found to be identical. All the six 23S rRNA genes
of this macrolide-susceptible strain had adenine at the
position 2058 (E. coli numbering). These sequences con-
firmed that the macrolide-susceptible strain ATCC
700294 has no known macrolide causing mutation at the
23S rRNA, and that the mutations found at the 23S rRNA
genes of the strain ni4277 were not caused by a systematic
sequencing error.
In addition to the difference at the position 2058 of the
23S rRNA, another difference between the 23S rRNA gene
sequences of the macrolide-resistant strain ni4277 and
the macrolide-susceptible strain ATCC 700294 was
observed. At the position 2163 (E. coli numbering) there
was a cytosine in all the six 23S genes of the strain ni4277,
but thymine at the corresponding position in all the six
23S genes of the strain ATCC 700294. This position is not
known to be linked to macrolide resistance [20].
Genes coding for ribosomal proteins L4 and L22 were
sequenced, and the sequences were compared against
complete genome sequences of S. pyogenes using Fasta.
Comparisons showed that both ribosomal proteins of the
strain ni4277 were identical to the published wild-type L4
and L22 sequences at the amino acid level [18]. No muta-
tions known to cause macrolide resistance in S. pyogenes
were found [13,14].Annals of Clinical Microbiology and Antimicrobials 2004, 3 http://www.ann-clinmicrob.com/content/3/1/5
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Discussion
We studied the presence of efflux pumps in the strain
ni4277 by PCR. mef(A) or mrs(A) genes were not found.
This does not exclude, a previously unknown efflux mech-
anism as the cause of resistance. However, the macrolide
resistance phenotype in the strain ni4277 is not typical for
efflux pumps, which are rather specific and do not cause
resistance against all antibiotics that bind to 23S rRNA [9].
When compared to control strain ATCC 700294, the
strain ni4277 had high MIC values for all macrolides,
including 14- and 16- membered-ring macrolides, one
azalide antibiotic, two different lincosamides, one strep-
togramin B antibiotic and two different ketolides. These
antibiotics have different structures, but they all have
common target site, the bacterial ribosome. All these anti-
biotics bind to or at least are in close contact with the 23S
rRNA. So, most likely, target site modification rather than
efflux mechanism is the cause of resistance in the strain
ni4277.
The S. pyogenes strain ni4277 carries two mutations in the
23S rRNA genes (positions 2058 and 2163) when com-
pared to the corresponding genes from a macrolide-sus-
ceptible  S. pyogenes strain ATCC 700294. The other
mutated position, 2058, is located at the very conservative
part of the domain V of the 23S rRNA molecule. Adenine
at the corresponding position can be found in 23S rRNA
molecules of almost all bacteria [20,21]. The domain V
and the adenine at the position2058 are known to be
important for the binding of the macrolides to ribosomes.
In bacteria, mutations at this position are always linked to
the MLSB type of resistance or at least erythromycin resist-
ance [20]. The macrolide resistance pattern of the strain
ni4277 was of the MLSB type. It was resistant to mac-
rolides and clindamycin, and it had elevated MIC for
streptogramin B (quinupristin) when compared to con-
trol strain ATCC 700294. In addition, the strain ni4277
had elevated MIC values for ketolides. In general, the phe-
notype of the strain ni4277 is very similar to the pheno-
type of S. pyogenes strains with constitutively expressed
erm(B) methylase: highly resistant to all macrolides, lin-
cosamides, resistant to streptogramin B antibiotics and,
the most importantly, resistant to ketolides [5]. This phe-
notypic similarity supports our finding. If the adenine at
the position 2058 is mutated, this mutation produces
similar phenotype as if the adenine at the corresponding
position were methylated. Erm(B) and erm(TR) methyl-
ases as well as other known erythromycin resistance-caus-
ing methylases are known to methylate adenine at the
position 2058 in streptococci and in other bacteria [5,22].
In the strain ni4277 neither erm(B) gene nor any other
methylase was found by PCR. Also, it is unlikely that a
methylase would be the cause of the resistance in the
strain ni4277, because the most of the target sites of the
putative methylase were mutated. So the observed muta-
tions at the position 2058 of the 23S rRNA genes are the
most likely reason for MLSB type of resistance and for ele-
vated MICs for ketolides. The other mutated position
2163 is not evolutionary conserved. According to the
Comparative RNA Web Site, 31,40%, 13,64%, 52,48% of
the bacteria have adenine, cytosine or guanine at this posi-
tion, respectively, indicating that variation at this position
is a normal phenomenon among bacteria [21]. Nor is this
position known to interact with macrolides or been asso-
ciated with macrolide resistance [20]. So it is unlikely that
mutation at the position 2163 is the cause of the mac-
rolide resistance.
The strain ni4277 had elevated MICs for ketolides, when
compared to the control strain ATCC 700294. Telithro-
mycin MIC 16 µg/ml was so high, that although there are
no breakpoints available for telithromycin, this strain is
likely to be telithromycin resistant. This finding indicates
that a S. pyogenes strain can become telithromycin resist-
ant, without acquiring external genetic material. The pre-
viously described point mutation, cytosine to thymine, at
the position 2611 of the 23S rRNA of S. pyogenes [14] does
not result in telitromycin resistance. Based on our knowl-
edge, this is the first description of a S. pyogenes strain with
adenine 2058 to guanine mutation as a cause of mac-
rolide resistance. This strain was isolated from a throat
specimen. Thus, our finding also indicates that this kind
of mutation in S. pyogenes 23S rRNA genes can arise in a
clinical situation.
Conclusions
Known acquired erythromycin resistance methylases or
macrolide efflux pumps were not found in the S. pyogenes
strain ni4277. The ribosomal proteins L4 and L22 in this
strain were identical to corresponding genes of macrolide-
susceptible  S. pyogenes strain. The macrolide resistance
phenotype of this strain was similar to that of other bacte-
ria with adenine at the position 2058 modified or
mutated. Based on this data we conclude that the detected
mutation, adenine to guanine at the position 2058, in five
of the six 23S rRNA-coding genes, was the most probable
cause of macrolide resistance in the strain ni4277. Based
on our knowledge, this is the first description of this
mutation as the cause of macrolide, lincosamide and
ketolide resistance in a clinical isolate of S. pyogenes.
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